PMID-sentid Pub_year Sent_text compound_name comp_offset prot_official_name organism prot_offset 34887529-0 2022 Insulin and glucose metabolism with olanzapine and a combination of olanzapine and samidorphan: exploratory phase 1 results in healthy volunteers. 3-carboxamido-4-hydroxynaltrexone 83-94 insulin Homo sapiens 0-7 31919994-2 2020 As cytochrome P450 (CYP) 1A2 and CYP3A4 are the major enzymes involved in metabolism of olanzapine and samidorphan, respectively, physiologically based pharmacokinetic (PBPK) modeling was applied to predict any drug-drug interaction (DDI) potential between olanzapine and samidorphan or between OLZ/SAM and CYP3A4/CYP1A2 inhibitors/inducers. 3-carboxamido-4-hydroxynaltrexone 103-114 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 33-39 31919994-2 2020 As cytochrome P450 (CYP) 1A2 and CYP3A4 are the major enzymes involved in metabolism of olanzapine and samidorphan, respectively, physiologically based pharmacokinetic (PBPK) modeling was applied to predict any drug-drug interaction (DDI) potential between olanzapine and samidorphan or between OLZ/SAM and CYP3A4/CYP1A2 inhibitors/inducers. 3-carboxamido-4-hydroxynaltrexone 272-283 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 3-28 31919994-2 2020 As cytochrome P450 (CYP) 1A2 and CYP3A4 are the major enzymes involved in metabolism of olanzapine and samidorphan, respectively, physiologically based pharmacokinetic (PBPK) modeling was applied to predict any drug-drug interaction (DDI) potential between olanzapine and samidorphan or between OLZ/SAM and CYP3A4/CYP1A2 inhibitors/inducers. 3-carboxamido-4-hydroxynaltrexone 103-114 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 3-28 31919994-2 2020 As cytochrome P450 (CYP) 1A2 and CYP3A4 are the major enzymes involved in metabolism of olanzapine and samidorphan, respectively, physiologically based pharmacokinetic (PBPK) modeling was applied to predict any drug-drug interaction (DDI) potential between olanzapine and samidorphan or between OLZ/SAM and CYP3A4/CYP1A2 inhibitors/inducers. 3-carboxamido-4-hydroxynaltrexone 272-283 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 33-39 31919994-5 2020 CYP3A4 inhibition is predicted to have a weak effect on samidorphan exposure and negligible effect on olanzapine exposure. 3-carboxamido-4-hydroxynaltrexone 56-67 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 0-6 31919994-6 2020 CYP3A4 induction is predicted to reduce both samidorphan and olanzapine exposure. 3-carboxamido-4-hydroxynaltrexone 45-56 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 0-6 31040679-2 2019 Previously reported clinical trials have demonstrated the efficacy of the investigational agent buprenorphine/samidorphan (BUP/SAM) combination, an opioid-system modulator, for the adjunctive treatment of major depressive disorder. 3-carboxamido-4-hydroxynaltrexone 110-121 COMM domain containing 3 Homo sapiens 123-126 31254971-1 2019 Buprenorphine/samidorphan (BUP/SAM; ALKS 5461) is an investigational opioid system modulator for the adjunctive treatment of patients with major depressive disorder (MDD), who did not respond adequately to prior antidepressant therapy (ADT). 3-carboxamido-4-hydroxynaltrexone 14-25 COMM domain containing 3 Homo sapiens 27-30 31463821-0 2019 Characterization of the Pharmacokinetics of Samidorphan in Healthy Volunteers: Absolute Bioavailability and the Effect of Food and Age. 3-carboxamido-4-hydroxynaltrexone 44-55 renin binding protein Homo sapiens 131-134 30102427-1 2019 Buprenorphine/samidorphan combination (BUP/SAM) is an opioid system modulator being investigated as adjunctive treatment for major depressive disorder. 3-carboxamido-4-hydroxynaltrexone 14-25 COMM domain containing 3 Homo sapiens 39-42 30102427-2 2019 BUP/SAM is a fixed-dose combination of buprenorphine, a partial mu-opioid receptor agonist and kappa-opioid receptor antagonist, and samidorphan, a mu-opioid receptor antagonist added to address the abuse and dependence potential of buprenorphine. 3-carboxamido-4-hydroxynaltrexone 133-144 COMM domain containing 3 Homo sapiens 0-3 30102427-10 2019 These findings indicate that samidorphan substantially reduces the abuse potential of buprenorphine in the BUP/SAM combination. 3-carboxamido-4-hydroxynaltrexone 29-40 COMM domain containing 3 Homo sapiens 107-110